Evidence mapPaperPMID 41579023Full record

ArticleEuropean heart journal2026

Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study.

Konsta Teppo, K E Juhani Airaksinen, Tuija Vasankari, Anna Linko-Parvinen, Hanna-Mari Pallari, Tuomas Paana, Samuli Jaakkola, Helea Junes, Selma Salonen, Tuulia Tuominen and 4 more

Abstract read
In one paragraph

Article in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Functional Autoantibodies in Myocardial Diseases.JACC. Basic to translational science · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Konsta TeppoHeart Center, Turku University Hospital, Turku, Finland.ORCID 0000-0002-4460-0994
K E Juhani AiraksinenHeart Center, Turku University Hospital, Turku, Finland.ORCID 0000-0002-0193-568X
Tuija VasankariHeart Center, Turku University Hospital, Turku, Finland.
Anna Linko-ParvinenTyks Laboratories, Clinical Chemistry, Turku University Hospital, Turku, Finland.
Hanna-Mari PallariTyks Laboratories, Clinical Chemistry, Turku University Hospital, Turku, Finland.
Tuomas PaanaHeart Center, Turku University Hospital, Turku, Finland.ORCID 0000-0002-7441-0278
Samuli JaakkolaHeart Center, Turku University Hospital, Turku, Finland.
Helea JunesBiotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland.
Selma SalonenBiotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland.
Tuulia TuominenBiotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland.
Sara SimonenBiotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland.
Marjatta StrandbergEmergency Department, Turku University Hospital, Turku, Finland.
Tapio HellmanKidney Center, Turku University Hospital, Turku, Finland.ORCID 0000-0001-9453-5687
Saara WittfoothBiotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland.ORCID 0000-0002-7886-3477

Funding

Cardiovascular Research and Clinical Research FundFinnish Foundation
6 · The paper itself

Abstract

BACKGROUND AND

aimsElevated cardiac troponin levels are a frequent finding in emergency department patients, often without a clear cause. Current high-sensitivity cardiac troponin T (cTnT) assays measure intact and fragmented cardiac troponin T (total cTnT) molecules, without distinguishing between them. This study investigated whether measuring only intact and minimally fragmented cTnT (long cTnT) provides additional value for myocardial infarction (MI) identification.

methodsConsecutive emergency department patients with standard high-sensitivity cTnT levels (Roche Diagnostics) above the upper reference limit (≥14 ng/L) were recruited. Long cTnT levels were measured using a novel immunoassay. The additional diagnostic value of long cTnT in identifying patients with type 1 MI or any MI was assessed.

resultsA total of 1811 patients participated in the study, 1145 (63.2%) presenting with chest pain or dyspnoea. Overall, 205 (11.3%) had MI, including 148 classified as type 1 MI. Only .7% of patients in the lowest long cTnT tertile (<3.7 ng/L) had type 1 MI. The discriminative ability of long cTnT was superior to total cTnT in identifying patients with MI (area under curve [95% confidence intervals]) for any MI: .833 (.804-.863) vs .782 (.744-.819), and for type 1 MI: .839 (.807-.872) vs .777 (.735-.819), both (P < .001). Integrating the predictive data from long cTnT with total cTnT provided additional value in both reclassification and decision curve analyses, compared to total cTnT data alone.

conclusionsThe long cTnT assay demonstrated good diagnostic performance in identifying MI in patients with elevated total cTnT levels, with the potential to improve the accuracy of MI diagnosis.

Indexed as

Myocardial InfarctionTroponin TAgedBiomarkersFemaleHumansMaleMiddle AgedSensitivity and SpecificityBiomarkersTroponin TCardiac troponinLong cTnTMyocardial infarctionTroponin fragmentationType 1 myocardial infarction

Identifiers

PMID41579023
PMCPMC12831185

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.